Trial Profile
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2022
Price :
$35
*
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Helixmith; VM BioPharma
- 23 Apr 2021 According to a Helixmith media release, results from this study has been accepted for poster presentations at the virtual 2021 American Academy of Pain Medicine Annual Meeting (2021).
- 23 Sep 2019 According to a ViroMed Laboratories media release, Helixmith conducted an unblinded data review meeting in Chicago with internal/external experts.
- 23 Sep 2019 Primary endpoint has not been met. (Change in the average pain score), according to a ViroMed Laboratories media release.